Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...
Hosted on MSN
Eikon Therapeutics continues the IPO parade, raising $381M for cancer drug clinical trials
Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results